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Biol Blood Marrow Transplant 15:886-891, 2009 891Letters to the EditorWe suggest that regimens such as BEAM-alemtu-
zumab and Fly-Mel/ATG, which combine low toxicity
and NRM with significant antitumor efficacy should
be classified as neither RIC nor myeloablative regi-
mens, but ‘‘regimens of intermediate intensity’’ or
‘‘toxicity-reduced conditioning’’ regimens. This is par-
ticularly important in avoiding the categorization of
such regimens as ‘‘myeloablative’’ in registry compari-
sons of outcome of RIC versus myeloblative-condi-
tioned transplants.
REFERENCES
1. Giralt S, Ballen K, Rizzo D, et al. Reduced intensity conditioning
regimenworkshop: defining the dose spectrum. Report of a work-
shop convened by theCentre for International Blood andMarrow
Transplant Research. Biol Blood Marrow Transplant. 2009;15:
367-469.
2. Faulkner R, Craddock C, Byrne JL, et al. BEAM-Alemtuzumab
reduced intensity allogeneic stem cell transplantation for lympho-
proliferative diseases: GVHD toxicity and survival in 65 patients.
Blood. 2004;103:428-434.
3. Sureda A, Robinson S, Canals C, et al. Reduced-intensity condi-
tioning compared with conventional allogeneic stem-cell trans-
plantation in relapsed or refractory Hodgkin’s lymphoma: an
analysis from the Lymphoma Working Party of the Europen
Group for Blood and Marrow Transplantation. J Clin Oncol.
2008;26:455-462.
4. Marks R, Potthof K, Hahn J, et al. Reduced toxicity condi-
tioning with Fludarabine BCNU and Melphalan in alloge-
neic haemopoietic cell transplantation: particular activity
against advanced haematologic malignancies. Blood. 2008;
112:415-424.
Nigel H. Russell
Jennifer I. Byrne
Stephen P. Robinson
Nottingham University Hospital, Centre for Clinical Haematology,
Nottingham, UK
BMT Unit, University Hospital, Bristol, UK
Biol Blood Marrow Transplant 15: 890-891 (2009)
 2009 American Society for Blood and Marrow Transplantation
doi:10.1016/j.bbmt.2009.02.012Response to LetterWe appreciate the comments of Professor Russell
and his colleagues regarding the report of our work-
shop. Our intent with this manuscript was not to
‘‘include’’ or ‘‘exclude’’ any regimen but to get a sense
of how members of the ‘‘transplant community’’ view
the current criteria as well as operational definitions
of what constitutes a ‘‘reduced intensity regimen’’.
The criteria were for the most part accepted by the
workshop participants. The operational definitions,
however, were not universally accepted. We did not
exclude the combination of carmustine, etoposide,
cytarabine and melphalan (BEAM) as a RIC regimen,
although 2/3 of the attendants did not feel that this
regimen should be included in the operational defini-
tion of RIC. In practice, some retrospective reviews
have included BEAM among the regimens analyzed.
Professor Russell correctly recognizes the arbitrary na-
ture of some of these definitions. However, our manu-
script was not intended to include or exclude any
regimen in particular, but to get a sense of what was
the ‘‘feeling’’ of the transplant community. The
CIBMTR and the EBMT are working on a consensus
statement to clarify some of these issues. In the end,
more important than classifying a regimen as ablative
or not, is whether any specific regimen will be associ-
ated with better outcomes. This will only be deter-
mined by prospective randomized trials.
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